Cargando…
A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function
Upregulation of cytokines and chemokines is a frequent finding in multiple myeloma (MM). CCL3 (also known as MIP-1α) is a pro-inflammatory chemokine whose levels in the MM microenvironment correlate with osteolytic lesions and tumor burden. CCL3 and its receptors, CCR1 and CCR5, contribute to the de...
Autores principales: | Vallet, Sonia, Pozzi, Samantha, Patel, Kishan, Vaghela, Nileshwari, Fulciniti, MariaTeresa, Veiby, Petter, Hideshima, Teru, Santo, Loredana, Cirstea, Diana, Scadden, David T, Anderson, Kenneth C, Raje, Noopur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142423/ https://www.ncbi.nlm.nih.gov/pubmed/21403648 http://dx.doi.org/10.1038/leu.2011.43 |
Ejemplares similares
-
Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008) -
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008) -
Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013) -
The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010) -
The herpesvirus 8 encoded chemokines vCCL2 (vMIP-II) and vCCL3 (vMIP-III) target the human but not the murine lymphotactin receptor
por: Lüttichau, Hans R
Publicado: (2008)